GIP and GLP-1 on Gastric Emptying, Appetite and Insulin-glucose

Uppsala University15 enrolled

Overview

Academic phase 1 study which investigates the effects of the two incretin hormones glucose-insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) on gastric emptying, appetite, insulin release and glucose disposal in the body. The hypothesis is that incretin hormones not only stimulate insulin release but also inhibits gastric emptying. This effect can be utilized for further drug development.

Effects of GIP and GLP-1 on gastric emptying, appetite control and insulin release in relation to glucose levels in the bloodstream. Infusions of GIP and GLP-1 are given under simultaneous gastric emptying study and appetite questionnaires and blood sampling for analysis of insulin, glucose, and other gut hormones such as glucagon, ghrelin, and PYY, as well as those administered, GIP and GLP-1.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

DOUBLE

Enrollment

Conditions

Physiology Gastroenterology Endocrinology

Interventions

Glucose-insulinotropic peptide, Glucagon-like peptide-1OTHER

GIP 2 and 5 pmol/kg min GLP-1 0.7 pmol/kg min

Eligibility

Sex: ALLMin age: 18 YearsMax age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Men and women * 18-50 years old; * otherwise healthy and HIV and HCB, HCV negative Exclusion Criteria: * Age \>50, * all types of diseases and drug users.

Locations (1)

Karolinska University Hospital

Stockholm, Stockholm County, Sweden

Outcomes

Primary Outcomes

Gastric emptying rate

Time frame: 2005-2006

Secondary Outcomes

Plasma glucose, insulin release, appetite

Time frame: 2005-2006

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.